Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Brooks Laboratories Limited

Market Cap 1.09B 11.57M 10.11M 9.35M 8.73M 16.38M 16.5M 111M 43.23M 537M 43.43M 42.49M 1.87B P/E 2024
-12.2x
P/E 2025 -28.6x
Enterprise Value 1.17B 12.37M 10.8M 9.99M 9.33M 17.51M 17.64M 119M 46.21M 575M 46.43M 45.42M 2B EV / Sales 2024
3.16x
EV / Sales 2025 3.93x
Free-Float
43.99%
Yield 2024 *
-
Yield 2025 -
06-18 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
25-10-16 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
25-08-13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-28 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
25-02-13 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
24-12-26 Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024 CI
24-12-10 Brooks Laboratories Limited announced that it expects to receive INR 750 million in funding from Jalan Chemical Industries Private Limited, K M Visaria Family Trust CI
24-11-09 Brooks Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
1 day+4.99%
1 week+5.18%
Current month+7.23%
1 month+36.79%
3 months+33.00%
6 months-25.43%
Current year-12.64%
1 week 66.1
Extreme 66.1
70.01
1 month 54.54
Extreme 54.54
71.9
Current year 36.3
Extreme 36.3
82.44
1 year 36.3
Extreme 36.3
164.02
3 years 36.3
Extreme 36.3
198.86
5 years 36.3
Extreme 36.3
198.86
10 years 13.85
Extreme 13.85
198.86
Manager TitleAgeSince
Chief Executive Officer - 2026-05-31
President 57 2023-08-22
Compliance Officer 33 2024-12-25
Director TitleAgeSince
Director/Board Member 53 2022-11-22
Director/Board Member 62 2010-09-09
Director/Board Member - 2023-08-22
Change 5-day change 1-year change 3-year change Capi.($)
+4.99%+5.18%-46.86%-12.87% 20.82M
+1.34%+3.05%+11.88%+87.81% 46.74B
+0.90%+4.02%+51.42%+90.96% 34.33B
+4.73%+1.89%-5.60%+40.32% 11.57B
+1.37%-1.74%+13.42%+93.80% 11.42B
-0.95%+0.96%+37.43%+127.27% 9.09B
+1.11%-2.15%+16.27%+41.36% 6.98B
-0.98%+0.83%+33.92%+240.86% 6.62B
+4.29%+6.01%+50.84%-15.23% 6.55B
+1.32%-1.66%-34.40%-0.52% 5B
Average +1.81%+0.02%+12.83%+69.38% 13.83B
Weighted average by Cap. +1.38%+0.94%+23.48%+84.60%

Financials

2024 2025
Net sales 795M 8.41M 7.35M 6.8M 6.35M 11.91M 12M 80.79M 31.43M 391M 31.58M 30.89M 1.36B 826M 8.74M 7.63M 7.06M 6.59M 12.37M 12.46M 83.91M 32.65M 406M 32.8M 32.09M 1.41B
Net income -196M -2.07M -1.81M -1.68M -1.56M -2.94M -2.96M -19.91M -7.75M -96.33M -7.78M -7.62M -335M -99.67M -1.05M -922K -852K -796K -1.49M -1.5M -10.13M -3.94M -49M -3.96M -3.87M -170M
Net Debt 55.16M 584K 510K 472K 440K 827K 833K 5.61M 2.18M 27.12M 2.19M 2.14M 94.22M 75.39M 798K 697K 645K 602K 1.13M 1.14M 7.66M 2.98M 37.07M 3M 2.93M 129M
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Employees
323
Date Price Change Volume
26-06-22 70.01 +4.99% 20,569
26-06-19 66.68 -1.94% 12,640
26-06-18 68.00 +1.54% 29,948
26-06-17 66.97 -0.22% 7,156
26-06-16 67.12 -0.64% 17,963
  1. Stock Market
  2. Stocks
  3. BROOKS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!